Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment ***** umptions. Eagle remains a strong believer in AI but prefers constructing a portfolio that can perform across multiple outcomes rather than relying on one forecast. The firm believes current earnings can overstate underlying economics because semiconductor equipment is depreciated over several years, while free cash flow growth remains much weaker. It also expects competition and additional capacity across AI labs, hyperscalers, and semiconductors to eventually create winners and losers. These dynamics are encouraging Eagle to recycle capital toward attractive opportunities outside the most crowded AI trades while maintaining selective exposure to high-quality beneficiaries. The portfolio trades at a 20% market discount with faster expected EPS growth. Please review the Strategy's top five holdings for key selections in 2026.
In its second-quarter 2026 investor letter, Eagle Capital Management highlighted Danaher Corporation (NYSE:DHR). Danaher Corporation (NYSE:DHR) is a healthcare and life science tools company operating through Biotechnology, Life Sciences, and Diagnostics segments. On September 02, 2026, Danaher Corporation (NYSE:DHR) closed at $209.91 per share. Over the past month, Danaher Corporation (NYSE:DHR) returned 4.97%, and its shares gained 5.47% over the past 52 weeks. Danaher Corporation (NYSE:DHR) has a market capitalization of $147.56 billion.
Eagle Capital Management stated the following regarding Danaher Corporation (NYSE:DHR) in its Q2 2026 investor letter:
"High quality with low volatility (24% of capital): London Stock Exchange, Danaher Corporation (NYSE:DHR), S&P Global, Mastercard, A.J. Gallagher: Approximately a quarter of Eagle's portfolio is spread across a handful of superb businesses that exhibit high and stable margins, strong returns on capital, wide competitive advantages, and well above GDP growth. We expect the group to deftly navigate the integration of AI into their markets. Most operate with a combination of oligopoly/monopoly ***** ets, network effects, or regulatory moats. Danaher is a leading life sciences company, selling a broad mix of consumables and tooling for biological R&D and drug production.
A few years ago, these stocks were priced for perfection. Their attractive characteristics were prized, and the group traded at more than 30x earnings. Over the past five years, the businesses have grown significantly, while the stocks have de rated. Today, the group trades at a high teen multiple. In a market that is growing EPS at nearly 20%, their steady growth isn't scarce. However, as earnings in the economy nor

Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment ****** umptions. Eagle remains a strong believer in AI but prefers constructing a portfolio that can perform across multiple outcomes rather than relying on one forecast. The firm believes current earnings can overstate underlying economics because semiconductor equipment is depreciated over several years, while free cash flow growth remains much weaker. It also expects competition and additional capacity across AI labs, hyperscalers, and semiconductors to eventually create winners and losers. These dynamics are encouraging Eagle to recycle capital toward attractive opportunities outside the most crowded AI trades while maintaining selective exposure to high-quality beneficiaries. The portfolio trades at a 20% market discount with faster expected EPS growth. Please review the Strategy's top five holdings for key selections in 2026.
In its second-quarter 2026 investor letter, Eagle Capital Management highlighted Mastercard Incorporated (NYSE:MA). Mastercard Incorporated (NYSE:MA) is a leading global payment technology company that provides transaction processing and other payment-related products and services. On September 02, 2026, Mastercard Incorporated (NYSE:MA) closed at $588.14 per share. Over the past month, Mastercard Incorporated (NYSE:MA) returned 2.12% while its shares lost 1.26% over the past 52 weeks. Mastercard Incorporated (NYSE:MA) has a market capitalization of $515.22 billion.
Eagle Capital Management stated the following regarding Mastercard Incorporated (NYSE:MA) in its Q2 2026 investor letter:
High quality with low volatility (24% of capital): London Stock Exchange, Danaher, S&P Global, Mastercard Incorporated (NYSE:MA), A.J. Gallagher: Approximately a quarter of Eagle's portfolio is spread across a handful of superb businesses that exhibit high and stable margins, strong returns on capital, wide competitive advantages, and well above GDP growth. We expect the group to deftly navigate the integration of AI into their markets. Most operate with a combination of oligopoly/monopoly ****** ets, network effects, or regulatory moats. Mastercard operates as part of a global duopoly of payment rails and standards.
A few years ago, these stocks were priced for perfection. Their attractive characteristics were prized, and the group traded at more than 30x earnings. Over the past five years, the businesses have grown significantly, while the stocks have de rated. Today, the group trades at a high teen multiple. In a market that is growing EPS at nearly 20%, their steady growth isn't scarce. However, as earnings in the economy normalize back towards m

Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment ****** umptions. Eagle remains a strong believer in AI but prefers constructing a portfolio that can perform across multiple outcomes rather than relying on one forecast. The firm believes current earnings can overstate underlying economics because semiconductor equipment is depreciated over several years, while free cash flow growth remains much weaker. It also expects competition and additional capacity across AI labs, hyperscalers, and semiconductors to eventually create winners and losers. These dynamics are encouraging Eagle to recycle capital toward attractive opportunities outside the most crowded AI trades while maintaining selective exposure to high-quality beneficiaries. The portfolio trades at a 20% market discount with faster expected EPS growth. Please review the Strategy's top five holdings for key selections in 2026.
In its second-quarter 2026 investor letter, Eagle Capital Management highlighted Arthur J. Gallagher & Co. (NYSE:AJG). Arthur J. Gallagher & Co. (NYSE:AJG) provides insurance and reinsurance brokerage, consulting, and third-party property/casualty claims settlement and administration services to entities and individuals. On September 02, 2026, Arthur J. Gallagher & Co. (NYSE:AJG) closed at $264.46 per share. Over the past month, Arthur J. Gallagher & Co. (NYSE:AJG) was up 5.05%, while its shares lost 11.91% over the past 52 weeks. Arthur J. Gallagher & Co. (NYSE:AJG) has a market capitalization of $67.78 billion.
Eagle Capital Management stated the following regarding Arthur J. Gallagher & Co. (NYSE:AJG) in its Q2 2026 investor letter:
"High quality with low volatility (24% of capital): London Stock Exchange, Danaher, S&P Global, Mastercard, A.J. Gallagher: Approximately a quarter of Eagle's portfolio is spread across a handful of superb businesses that exhibit high and stable margins, strong returns on capital, wide competitive advantages, and well above GDP growth. We expect the group to deftly navigate the integration of AI into their markets. Most operate with a combination of oligopoly/monopoly ****** ets, network effects, or regulatory moats. A.J. Gallagher is a commercial insurance broker that continues to gain share in a consolidating industry.
A few years ago, these stocks were priced for perfection. Their attractive characteristics were prized, and the group traded at more than 30x earnings. Over the past five years, the businesses have grown significantly, while the stocks have de rated. Today, the group trades at a high teen multiple. In a market that is growing EPS at nearly 20%, their steady growth isn't scarce. Howev

Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment **** umptions. Eagle remains a strong believer in AI but prefers constructing a portfolio that can perform across multiple outcomes rather than relying on one forecast. The firm believes current earnings can overstate underlying economics because semiconductor equipment is depreciated over several years, while free cash flow growth remains much weaker. It also expects competition and additional capacity across AI labs, hyperscalers, and semiconductors to eventually create winners and losers. These dynamics are encouraging Eagle to recycle capital toward attractive opportunities outside the most crowded AI trades while maintaining selective exposure to high-quality beneficiaries. The portfolio trades at a 20% market discount with faster expected EPS growth. Please review the Strategy's top five holdings for key selections in 2026.
In its second-quarter 2026 investor letter, Eagle Capital Management highlighted S&P Global Inc. (NYSE:SPGI). S&P Global Inc. is a financial services and **** ytics company that provides benchmarks, data, **** ytics, and workflow solutions in the global capital, energy, commodity, and automotive markets. On September 02, 2026, S&P Global Inc. closed at $431.71 per share, reflecting a market capitalization of $127.27 billion. S&P Global Inc. posted a one‑month return of 6.40%, while its shares lost 14.62% over the past 52 weeks.
Eagle Capital Management stated the following regarding S&P Global Inc. (NYSE:SPGI) in its Q2 2026 investor letter:
"High quality with low volatility (24% of capital): London Stock Exchange, Danaher, S&P Global Inc. (NYSE:SPGI), Mastercard, A.J. Gallagher: Approximately a quarter of Eagle's portfolio is spread across a handful of superb businesses that exhibit high and stable margins, strong returns on capital, wide competitive advantages, and well above GDP growth. We expect the group to deftly navigate the integration of AI into their markets. Most operate with a combination of oligopoly/monopoly **** ets, network effects, or regulatory moats. S&P Global owns the S&P ratings franchise, S&P Indexes, Platts, and Capital IQ.
A few years ago, these stocks were priced for perfection. Their attractive characteristics were prized, and the group traded at more than 30x earnings. Over the past five years, the businesses have grown significantly, while the stocks have de rated. Today, the group trades at a high teen multiple. In a market that is growing EPS at nearly 20%, their steady growth isn't scarce. However, as earnings in the economy normalize back towards mid businesses should demonstrate significant outperfor

Investment management company First Pacific Advisors recently released its "FPA Queens Road Small Cap Value Fund" second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Fund returned 27.02% in the first half of 2026, outperforming the Russell 2000 Value Index's 22.99% gain and the S&P 600 Index's 23.90% return. Small-cap earnings growth also began accelerating relative to large caps, while the small-cap technology sector surged nearly 100% in 26H1. The fund's technology holdings gained 72.39%, contributing 14.87 percentage points, compared with a 95.27% return and 7.10-point contribution from the benchmark's technology sector. Excluding IT and cash, the Fund contributed 12.73% versus 15.89% for the Russell 2000 Value Index; on a fully invested basis, the figures were 16.62% and 17.59%, respectively. The portfolio continued to trim appreciated technology holdings amid the AI-driven rally, while maintaining a bottom-up approach and avoiding beaten-down SaaS stocks due to the widening range of AI-related outcomes. The fund also eliminated about $62 million in capital gains during Q2 and approximately $140 million year-to-date through July, while ending the quarter with 10.2% in cash. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its second-quarter 2026 investor letter, FPA Queens Road Small Cap Value Fund highlighted stocks like Vontier (NYSE:VNT). Vontier (NYSE:VNT) provides technology and solutions for mobility, transportation, and industrial markets, including fueling, fleet, and repair applications. The one-month return of Vontier (NYSE:VNT) was -4.76% while its shares traded between $27.25 and $48.20 over the last 52 weeks. On August 31, 2026, Vontier (NYSE:VNT) stock closed at approximately $32.76 per share, with a market capitalization of about $4.35 billion.
FPA Queens Road Small Cap Value Fund stated the following regarding Vontier (NYSE:VNT) in its Q2 2026 investor letter:
"In Q2 we added new position. Vontier (NYSE:VNT) manufactures tanks, pumps and payment systems for gas stations. The company was a 2021 spinoff from Fortive, which itself was the spinoff of Danaher's lower growth industrial ****** ets. Since 2021, Vontier has been dealing with headwinds following a pull forward of sales from changing payment standards (EMV) and reorganizing the disparate collection of businesses that were originally acquired by Danaher. At their November 2025 Investor Day, Vontier made the cogent argument that they benefit from potential sales to the growing convenience store end market. We believe that shares are attractively priced at roughly 9x earnings."

#NYSE #fund #small #technology

Washington, the District Of Columbia-based Danaher Corporation (DHR) designs, manufactures, and markets professional, medical, research, and industrial products and services. The company is valued at $151.9 billion by market cap.
Companies worth $10 billion or more are generally described as "large-cap stocks," and DHR definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the diagnostics & research industry. DHR's competitive strengths come from its portfolio of high-margin, mission-critical tools in biotech, diagnostics, and life sciences. Strong positions in regulated, R&D-heavy markets give it pricing power and resilience, even in downturns.
Dear Sandisk Stock Fans, Mark Your Calendars for August 31
Wu-Tang Clan Member Raekwon Is a Palantir 'OG,' Visiting Headquarters 16 Years After Receiving His Custom PLTR Jacket
Dear Palantir Stock Fans, Here's What Maven's Billion-Dollar ARR Means for PLTR

#palantir

Aristotle Capital Management, LLC, an investment management company, released its "Value Equity Fund" Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while its 1.99% year-to-date return also lagged the Russell 1000 Value Index's 16.26% and the S&P 500's 10.21%. The Fund attributed the performance gap largely to limited exposure to the AI infrastructure spending boom, noting that the U.S. has about 4,000 existing data centers and nearly 3,000 more planned or under construction, while AI-related demand has created bottlenecks in processors and memory. The letter highlighted the scale of the cycle, with industry cash flows in key AI hardware areas rising sharply, while the Russell 1000 Value Index's top 10 contributors gained an average 182% year to date and accounted for 9.29 percentage points of the index's 16.23% return. Looking ahead, the fund expects investors to eventually reassess the sustainability of current AI infrastructure earnings and valuations. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its second-quarter 2026 investor letter, Aristotle Value Equity Fund highlighted stocks like Danaher Corporation (NYSE:DHR). Danaher Corporation (NYSE:DHR) develops life sciences, diagnostics, and biotechnology products and technologies used across healthcare and research markets. The one-month return of Danaher Corporation (NYSE:DHR) was 10.62% while its shares traded between $160.93 and $242.80 over the last 52 weeks. On August 27, 2026, Danaher Corporation (NYSE:DHR) stock closed at approximately $215.36 per share, with a market capitalization of about $155.62 billion.
Aristotle Value Equity Fund stated the following regarding Danaher Corporation (NYSE:DHR) in its Q2 2026 investor letter:
We first invested in Danaher Corporation (NYSE:DHR), a company focused on biotechnology, life sciences and diagnostics, in the second quarter of 2016, attracted by its disciplined capital allocation, differentiated operating culture and consistent FREE cash flow generation. The business is distinguished by a portfolio of market-leading franchises and a high mix of recurring consumables revenue tied to a large installed base. Its differentiated operating culture, anchored by the Danaher Business System, has historically enabled the company to be a highly effective acquirer, consistently integrating new businesses, expanding margins and driving strong FREE cash flow generation. Over our decade-long holding period, Danaher successfully transformed itself from a diversified industrial company into a more focused healthcare business. This evolution included the spinoffs of Fortive, Envista, and Veralto, as well as the acquisition and integration of key ***** ets such as Pall, Cepheid and Cytiva. The company also increased the contribution from re

Healthcare investors often face a difficult decision when choosing between companies with very different paths to growth. Some businesses are emerging from temporary industry slowdowns, while others continue compounding through durable competitive advantages.
Danaher Corporation (NYSE:DHR) and Intuitive Surgical (NASDAQ:ISRG) illustrate that contrast perfectly. Danaher (NYSE:DHR) is beginning to benefit from improving life sciences spending after several challenging years, whereas Intuitive Surgical (NASDAQ:ISRG) continues to expand one of the healthcare industry's strongest recurring revenue businesses through robotic surgery. Both companies reported encouraging results, but the question for investors is whether a cyclical recovery or a structural growth story offers the better long-term opportunity.
The strongest argument supporting Danaher is that its recovery appears to be broadening. Its Life Sciences business delivered its strongest performance in several years, and although bioprocessing revenue was affected by customer project timings, the underlying order trends remained strong, with bioprocessing orders growing mid-teens in the quarter. This shows that the underlying demand for bioprocessing remained solid, including consumables and equipment necessary to make biologic drugs.
Danaher Corporation (NYSE:DHR) also stated that a little over $100 million of revenue has shifted into next year, primarily from the second and third quarters. This suggests that customer demand has been delayed rather than cancelled, potentially supporting future revenue growth.
Intuitive Surgical (NASDAQ:ISRG), by contrast, continues to benefit from the strength of a business model that has consistently generated growth regardless of broader industry cycles. Intuitive Surgical's (NASDAQ:ISRG) business model remains one of its biggest competitive advantages. Approximately 85% of total revenue came from recurring sources during the quarter, providing investors with significant revenue visibility as the installed base continues to grow.

#danaher #surgical

Healthcare investors are beginning to see signs of recovery across several parts of the industry, but not every recovery looks the same. Danaher (NYSE:DHR) is benefiting from improving demand in life sciences after a prolonged post-pandemic slowdown, while Medtronic (NYSE:MDT) is finally beginning to show the results of years of investment in new products and operational execution. Both companies reported encouraging results, but very different factors are driving their recoveries. The question for investors is which recovery story offers the greater long-term upside.
The strongest argument supporting Medtronic (NYSE:MDT) is that its turnaround is no longer being driven by cost controls alone. The company's latest results suggest its newer growth platforms are beginning to contribute meaningfully to revenue. The company reported its highest annual revenue growth in 10 years in its fiscal Q4 and full-year 2026 results. Q4 revenue reached $9.8 billion, up 9.9% as reported and 6.6% organic, and FY 26 revenue was $36.4 billion, with adjusted revenue of $36.3 billion, up 8.4% as reported and 5.8% organic. The trends suggest that the company is exhibiting continued operational rigor and building momentum in its highest growth opportunities, including Affera, Symplicity, Hugo, Altaviva, and Stealth AXiS.
Furthermore, Medtronic's (NYSE:MDT) cardiac segment is emerging as one of the most prominent growth drivers for the company, as the Cardiac Ablation Solutions revenue rose 78% globally, including 124% U.S. growth. That is significant for investors because cardiac devices remain one of the company's highest-margin and fastest-growing businesses.
Danaher's story, however, depends much more on improving customer spending across its Life Sciences business, which delivered its strongest performance in several years. Although bioprocessing revenue was affected by customer project timings, the underlying order trends remained strong, with bioprocessing orders growing mid-teens in the quarter. This shows that the underlying demand for bioprocessing remained strong, which includes consumables and equipment necessary to make biologic drugs.
Danaher Corporation (NYSE:DHR) also stated that a little over $100 million of revenue has shifted into next year, primarily from the second and third quarters. This suggests that customer demand has been delayed rather than cancelled, potentially supporting future revenue growth.

#revenue

Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its "Mid Cap Strategy". A copy of the Q2 2026 investor letter can be downloaded here. In the quarter, equity markets posted strong returns as resilient economic growth and robust corporate earnings supported investor sentiment, although AI-related companies continued to dominate market leadership. Technology was the strongest-performing sector, while industrials also advanced and energy lagged as oil prices declined. The Fund returned 7.92% and the Russell Midcap Index returned 13.83%. Health care holdings were the largest positive contributor, supported by strength across managed care, diagnostics, and life sciences. However, stock selection and an underweight position in information technology remained the main relative headwinds. The strategy maintained limited exposure to highly valued semiconductor and memory companies, reflecting concerns that current valuations **** ume an extended period of elevated AI spending. It also continued to **** s software and services businesses individually based on how AI may affect their long-term competitive positions. Management emphasized higher-quality companies, attractive valuations, capital preservation, and durable long-term compounding while remaining cautious about elevated valuations, concentrated leadership, and the sustainability of the current AI investment cycle. Please review the Strategy's top five holdings for its key selections.
In its second-quarter 2026 investor letter, Diamond Hill Capital Mid Cap Strategy highlighted Veralto Corporation (NYSE:VLTO) as a newly added position. Veralto Corporation (NYSE:VLTO) provides water **** ytics, water treatment, marking and coding, and packaging and color solutions. On August 4, 2026, Veralto Corporation (NYSE:VLTO) closed at $96.45 per share. One-month return of Veralto Corporation (NYSE:VLTO) was 5.13% and its shares lost 10.26% over the past 52 weeks. Veralto Corporation (NYSE:VLTO) has a market capitalization of $23.12 billion with a 52-week trading range between $80.03 - $110.11.
Diamond Hill Capital Mid Cap Strategy stated the following regarding Veralto Corporation (NYSE:VLTO) in its Q2 2026 investor letter:
"Water testing and treatment provider Veralto Corporation (NYSE:VLTO) was spun out of Danaher in late 2023. We initiated a position as we believe the market has underappreciated the company's resilient business model, strong profitability and disciplined capital allocation amid the current chase for revenue growth in data center-related industries."

#veralto #NYSE #capital

Danaher Corporation (NYSE:DHR) delivered second-quarter results on July 21, marked by core growth improving compared to the previous quarter, along with disciplined execution that drove high-single-digit adjusted EPS growth. Despite beating earnings estimates, raising its adjusted EPS guidance, and reporting improving trends in its Life Sciences business, investors remain unconvinced following weaker-than-expected bioprocessing revenue and a reduction in its full-year core revenue growth outlook.
The mixed results raise an important question for investors: Is Danaher Corporation's (NYSE:DHR) recent weakness creating a buying opportunity, or are growth concerns beginning to outweigh its long-term strengths?
One of the biggest positives from the quarter was Danaher Corporation's (NYSE:DHR) Life Sciences business, which delivered its strongest performance in several years. Although bioprocessing revenue was affected by customer project timings, the underlying order trends remained strong, with bioprocessing orders growing mid-teens in the quarter. This shows that the underlying demand for bioprocessing remained strong, which includes consumables and equipment necessary to make biologic drugs.
Danaher Corporation (NYSE:DHR) stated that a little over $100 million of revenue has shifted into next year, primarily from the second and third quarters. This distinction matters because it suggests that customer demand has been delayed rather than cancelled, potentially supporting future revenue growth. While the academic and government markets have largely stabilized, more supportive government policies would be essential to safely call it an inflection point.
Key fiscal Q2 2026 results included a 5.5% year-over-year growth in revenue to $6.3 billion, as well as a 60% year-over-year rise in net earnings to $870 million, or $1.23 per diluted common share. The company also reported that non-GAAP core revenue increased 3.0% year-over-year and non-GAAP core revenue, excluding respiratory testing revenue, increased 4.5% year-over-year, suggesting improving trends in the company's operations. According to data compiled by LSEG, Danaher Corporation (NYSE:DHR) profits for the quarter reached $1.94 per share, above estimates of $1.83 per share.

#results

Agilent Technologies Inc. (NYSE:A) just extended its diagnostics franchise into one of oncology's toughest corners. On July 23, the company said European regulators had certified its PD-L1 IHC 22C3 pharmDx test, Code SK006, as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma. That lets pathologists flag patients who might benefit from Merck's Keytruda. It is a narrow, technical-sounding approval, but it adds up to something bigger: Agilent's diagnostics business keeps racking up new indications while competitors scramble to keep pace.
Bull Case: A Diagnostics Machine That Keeps Adding Indications
This is now the eighth CE-marked indication for the 22C3 pharmDx ****** ay in the EU, following FDA approval of a related PD-L1 test (28-8 pharmDx) for esophageal and gastric cancers just nine days earlier. Each new label doesn't require Agilent to build a new product; it just extends the reach of an ****** ay already running in labs worldwide, which is a high-margin way to grow. Agilent has also been adding inorganically, closing its acquisition of Biocare Medical in June to deepen its clinical pathology reach, the same market where this new ovarian cancer approval lives. Together, the pipeline of regulatory wins and the acquisition strategy point to a company compounding its diagnostics footprint one label at a time rather than swinging for one blockbuster product.
Bear Case: A Crowded Diagnostics Field With A Scarier Neighbor
Companion diagnostics is not Agilent's alone to win. Danaher Corporation (NYSE:DHR), through its Leica Biosystems unit, competes directly for the same pathology lab budgets and just agreed on July 14 to acquire StatLab Medical Products to strengthen its own histology and AI-pathology pipeline. Danaher's own stock cratered 14% on July 21 after it trimmed its core revenue growth outlook, even though it beat on earnings and raised its profit forecast.

#pharmdx #pathology

July 22 (Reuters) - Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at ‌about $1.5 billion, to expand the drugmaking equipment provider's presence in ‌the fast-growing cell therapy market.
The acquisition gives Repligen access to BioLife's technology to preserve cells throughout the manufacturing process and the supply chain, as well as its portfolio of cell-processing tools and high-margin consumables business.
Larger peer Danaher on Tuesday signaled a recovery in demand for bioprocessing products, including ‌equipment and consumables used ⁠to manufacture biologic drugs, as biotech and pharmaceutical companies ramp up spending after a broader slowdown in research ⁠spending and customer inventories in recent years.
The acquisition comes a month after German drugmaker Merck KGaA's $11.3 billion deal to buy Bio-Techne, underscoring growing interest in companies making tools for drug development.
BioLife shareholders will receive $11.25 in ‌cash and 0.1442 shares of Repligen for each share, valuing the cell therapy tools supplier at $31 per share — a premium of about 6.2% to BioLife's last close.

#tools #billion #equipment #growing

To say Danaher Corp.
DHR
+6.76%
had a downbeat reaction to earnings is an understatement. We regret the timing of our
stock pick
, though investors with longer time horizons will want to stay the course.
DHR
+6.76%
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

#corp #downbeat #reaction

L1 Capital, an investment management firm, released its "L1 Capital International Fund" (unhedged) second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter discusses the current investment environment as a 'two-speed' but resilient global economy, accompanied by an uncertain future. The letter explores the potential of an AI bubble, distinguishing between strong fundamentals and speculative momentum. Additionally, the market displays a 'narrow' character, marked by high exuberance and ******* ounced over-pessimism. Against this backdrop, the Fund returned +2.6% (net of fees) during the June 2026 quarter, compared to the benchmark return of +12.5% (all in A$). The underperformance was driven more by which investments were not held in the Fund. The Fund remains focused on quality, valuation and the avoidance of permanent capital loss, and believes the portfolio is positioned to deliver attractive risk-adjusted returns for patient investors. In addition, you can check the Fund's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, L1 Capital International Fund highlighted CDW Corporation (NASDAQ:CDW). CDW Corporation (NASDAQ:CDW) is an information technology (IT) solutions company that operates through its Commercial, Government, and Education segments. On July 17, 2026, CDW Corporation (NASDAQ:CDW) closed at $133.24 per share. One-month return of CDW Corporation (NASDAQ:CDW) was 7.83%, and its shares lost 24.67% over the past 52 weeks. CDW Corporation (NASDAQ:CDW) has a market capitalization of $17.02 billion.
L1 Capital International Fund stated the following regarding CDW Corporation (NASDAQ:CDW) in its Q2 2026 investor update:
"CDW Corporation (NASDAQ:CDW) is a leading provider of products and solutions in the information technology (IT) industry in North America and the U.K. It acts as a value-added reseller for many of the leading IT businesses. Management is executing solidly in subdued market conditions. Most of the AI implications for CDW are second-order. For example, clients may spend less on the products and solutions sold by CDW and more on AI-centric solutions.
We divested CDW to fund larger investments in several high-quality businesses that are not AI sensitive and trading below our ******* sed fair value, thus offering a compelling investment opportunity particularly for investors who are less driven by short term momentum and have a longer-term investment horizon. Examples include American Express, Apollo Group, Danaher, HCA and ICE."

#corporation #solutions

Palm Valley Capital Management, an investment management firm, has issued the second-quarter 2026 investor letter for the "Palm Valley Capital Fund." A copy of the letter can be downloaded here. In the second quarter, the fund's investor class gained 1.80%, while the S&P SmallCap 600 rose 19.7% and the Morningstar Small Cap Total Return Index returned 14.0%. The Strategy primarily focused on small-cap categories, allocating 75% to cash equivalents. This led to underperformance relative to benchmarks. The Fund is currently seeking more small-cap opportunities that meet its return criteria and will act swiftly if market conditions improve. The Index benefited from strong contributions from data center construction and biotech sectors, while the energy industry lagged. Additionally, reviewing the fund's top five holdings can reveal its best investments in 2026.
In its second-quarter 2026 investor letter, Palm Valley Capital Management highlighted Vontier Corporation (NYSE:VNT) as a newly added position. Vontier Corporation (NYSE:VNT) is a global industrial technology and mobility solutions company that operates through mobility technologies, repair solutions, and environmental and fueling solutions segments. On July 7, 2026, Vontier Corporation (NYSE:VNT) closed at $28.49 per share, reflecting a market capitalization of $4.01 billion. Vontier Corporation (NYSE:VNT) posted a one-month return of 0.60%, while its shares lost 25.56% over the past 52 weeks.
Palm Valley Capital Management stated the following regarding Vontier Corporation (NYSE:VNT) in its Q2 2026 investor letter:
"The Fund acquired three new positions during the second quarter: The Clorox Company (ticker: CLX), Molson Coors Beverage Company (ticker: TAP), and Vontier Corporation (NYSE:VNT). Vontier sells the equipment, software, and recurring services that help convenience stores pump gas and process payments, repair shops diagnose problems, and car washes operate efficiently. It was spun out of Fortive Corporation in 2020, which itself was formerly part of Danaher. Key operations include fueling equipment and payment systems through the brands Invenco and Gilbarco Veeder-Root, vehicle repair and diagnostics tools through Matco Tools, and car wash technology through DRB. The company touches a large portion of the world's fuel transactions, since its equipment is installed at hundreds of thousands of fuel sites globally. Vontier enjoyed a significant temporary tailwind, peaking in 2021, when U.S. gas stations were required to upgrade payment terminals at the pump to support EMV chip card transactions due to shifting fraud liability rules. Some investors have long-term concerns about the company's relevance as the transportation fleet moves away from internal combustion engines. Vontier has become more fuel agnostic in recent years, with its products serving vehicles powered by gasoline, electricity, and hydrogen. The firm owns a leading provider of electric vehicle (EV) charging softw

Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the "Artisan Mid Cap Value Fund". A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and negative sentiment. The Fund's Investor Class: ARTQX returned -4.93%, Advisor Class: APDQX declined by -4.90%, and Institutional Class: APHQX fell by -4.97%, all trailing the Index's 3.68% gain. The equity market in the quarter was mixed, with mid- and small-cap indices showing resilience despite lagging large-cap growth stocks. Volatility increased, initially fueled by interest in AI and private credit, but escalated after the outbreak of war in Iran, leading to rising oil prices. Sector performance varied, with energy leading the gains. The Fund continues to seek companies capable of value growth during market dislocations at attractive entry points. Also, review the Fund's top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted Veralto Corporation (NYSE:VLTO) as a newly added position. Veralto Corporation (NYSE:VLTO) is an industrial technology company specializing in water **** ytics, water treatment, marking and coding, and packaging and color solutions. On July 7, 2026, Veralto Corporation (NYSE:VLTO) closed at $93.10 per share, reflecting a market capitalization of $22.86 billion. Veralto Corporation (NYSE:VLTO) posted a one-month return of 12.68%, while its shares lost 9.06% over the past 52 weeks.
Artisan Mid Cap Value Fund stated the following regarding Veralto Corporation (NYSE:VLTO) in its Q1 2026 investor letter:
"We initiated six new positions in Q1, representing an above-average rate of new purchase activity. Increased market volatility and greater dispersion in US equities during the quarter created more opportunities to add new names that meet our three margin-of-safety criteria: attractive business economics, sound financial condition and attractive valuation. Additionally, we sought to use recent volatility to upgrade the portfolio's quality. Our three largest new buys by position size were Brown & Brown, Veralto Corporation (NYSE:VLTO) and IQVIA Holdings.
Veralto is a provider of water quality and product quality solutions that was spun out of Danaher in 2023. The shares have traded off from prior levels and now reflect more modest expectations, creating an opportunity to invest in a historically high-quality compounder at a more reasonable valuation. The company's conservative guidance for full-year EPS disappointed the market. From a business economics perspective, Veralto benefits from attractive end markets and durable competitive advantages. Its Water Quality and Product Quality & Innovation segments operate in niches characterized by high regulatory requirements,

Danaher Corporation (NYSE:DHR) is one of the best non-tech stocks to buy according to ******* ysts. Masimo, Danaher Corporation's (NYSE:DHR) specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, announced on June 22, FDA 510(k) clearance for an opioid-induced respiratory depression detection capability integrated into the Radius VSM® wearable continuous patient monitor. Supported by Masimo's next-generation smartSET™ pulse oximetry sensor platform, the new feature employs advanced pattern recognition, which ******* yzes continuous physiologic data, allowing clinicians to identify early signs of respiratory compromise in hospital patients receiving opioid therapy.
In a separate development, Wolfe Research downgraded Danaher Corporation (NYSE:DHR) to Peer Perform from Outperform on June 1 without ******* igning a price target after ******* uming coverage of the name. It stated that growth forward and backward is similar, and Thermo Fisher is "a little cheaper on P/E". It added that the Masimo (MASI) transaction "confused us about DHR's identity."
Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, industrial, and commercial products and services, making it a significant diagnostics stock. It operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions.
While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Madison Investments, an investment advisor, released its first-quarter 2026 investor letter for the "Madison Large Cap Fund". A copy of the letter is available to download here. The Madison Large Cap Fund (Class I) declined 2.7% in the quarter, outperforming the S&P 500's -4.33% return. The fund focuses on long-term capital appreciation. The quarter saw a shift in the equity market beyond the mega-cap technology stocks into physical economy stocks, influenced by fears of AI disruption. Additionally, rising commodity prices due to the Middle East conflict reignited inflation concerns, benefiting sectors such as Energy, Materials, Utilities, Staples, and Real Estate, which the Fund does not invest in, impacting its relative performance. Please review the Fund's top five holdings to gain insights into their key selections for 2026.
In its first-quarter 2026 investor letter, Madison Large Cap Fund highlighted Agilent Technologies, Inc. (NYSE:A). Agilent Technologies, Inc. (NYSE:A) is a leading global provider of application-focused solutions to the life sciences, diagnostics, and applied chemical markets. On June 15, 2026, Agilent Technologies, Inc. (NYSE:A) closed at $130.59 per share. One-month return of Agilent Technologies, Inc. (NYSE:A) was 14.75%, and its shares gained 17.50% over the past 52 weeks. Agilent Technologies, Inc. (NYSE:A) has a market capitalization of $36.88 billion.
Madison Large Cap Fund stated the following regarding Agilent Technologies, Inc. (NYSE:A) in its Q1 2026 investor letter:
"Our two life science tools investments, Danaher and Agilent Technologies, Inc. (NYSE:A), round out the top five detractors. Both companies reported results broadly consistent with expectations. However, while each respective company's outlook for 2026 calls for continued end market recovery, it was at a slower pace than investors hoped. Furthermore, investors appear to also have ascribed some level of "AI risk" to these companies on the belief that AI technology could enable customers to simulate research experiments, thus reducing the need to purchase instruments and consumables used for physical experiments in the lab. We believe that there is a low likelihood that this will ultimately occur, and even if it did happen, early-stage R&D activity represents a very small percentage of Agilent and Danaher's revenue."
Agilent Technologies, Inc. (NYSE:A) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 63 hedge fund portfolios held Agilent Technologies, Inc. (NYSE:A) at the end of the first quarter, compared to 71 in the previous quarter. In the second quarter of fiscal 2026, Agilent Technologies, Inc. (NYSE:A) reported $1.83 billion in revenue, up 6.3% on a core basis, exceeding the high end of guidance. While we acknowledge the potential of Agilent Technologies, Inc. (NYSE:A) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If yo

Madison Investments, an investment advisor, released its first-quarter 2026 investor letter for the "Madison Large Cap Fund". A copy of the letter is available to download here. The Madison Large Cap Fund (Class I) declined 2.7% in the quarter, outperforming the S&P 500's -4.33% return. The fund focuses on long-term capital appreciation. The quarter saw a shift in the equity market beyond the mega-cap technology stocks into physical economy stocks, influenced by fears of AI disruption. Additionally, rising commodity prices due to the Middle East conflict reignited inflation concerns, benefiting sectors such as Energy, Materials, Utilities, Staples, and Real Estate, which the Fund does not invest in, impacting its relative performance. Please review the Fund's top five holdings to gain insights into their key selections for 2026.
In its first-quarter 2026 investor letter, Madison Large Cap Fund highlighted Accenture plc (NYSE:ACN). Accenture plc (NYSE:ACN), a professional services company that focuses on consulting, technology and outsourcing, was among the leading detractors from performance during the quarter. On June 12, 2026, Accenture plc (NYSE:ACN) closed at $170.28 per share. One-month return of Accenture plc (NYSE:ACN) was -4.09%, and its shares lost 45.83% over the past 52 weeks. Accenture plc (NYSE:ACN) has a market capitalization of $104.79 billion.
Madison Large Cap Fund stated the following regarding Accenture plc (NYSE:ACN) in its Q1 2026 investor letter:
"The bottom five detractors for the quarter were Gartner, Danaher, Workday, Accenture plc (NYSE:ACN), and Agilent Technologies. At Accenture, performance continues to be muted as clients eschew large discretionary projects and Department of Government Efficiency ("DOGE") efforts weigh on its Public Service customer group. While we've long admired Accenture's ability to retool its nearly 800,000 employee workforce to adapt and commercialize the latest technology with its large enterprise customer base, we sold our position in the quarter. The company has recently started to limit its disclosure of customer bookings related to AI technology and evolved its capital allocation framework to emphasize acquisitions outside its core business. In light of these developments and range of outcomes related to the impact of AI on its business, we elected to sell our investment."
Accenture plc (NYSE:ACN) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 64 hedge fund portfolios held Accenture plc (NYSE:ACN) at the end of the first quarter, up from 71 in the previous quarter. In the first quarter of fiscal 2026, Accenture plc (NYSE:ACN) reported revenues of $18.7 billion, reflecting a 5% increase in local currency. While we acknowledge the potential of Accenture plc (NYSE:ACN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI sto